Xuefeng Sun

机构：Hebei Medical University, Jinan University, State Administration of Traditional Chinese Medicine of the People's Republic of China, Chinese PLA General Hospital, Southern University of Science and Technology, China General Nuclear Power Corporation (China), Hebei General Hospital, Suzhou Research Institute, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University · ORCID：0000-0003-2984-8905

发表论文 173 篇 · 总被引 3229 次 · h-index 36

代表论文

• Association between sarcopenia and frailty in elderly patients with chronic kidney disease (2023 · Journal of Cachexia Sarcopenia and Muscle · 被引 66)
• Targeted VEGFA therapy in regulating early acute kidney injury and late fibrosis (2023 · Acta Pharmacologica Sinica · 被引 43)
• The PI3K-Akt-mTOR pathway mediates renal pericyte-myofibroblast transition by enhancing glycolysis through HKII (2023 · Journal of Translational Medicine · 被引 42)
• Depleting profibrotic macrophages using bioactivated in vivo assembly peptides ameliorates kidney fibrosis (2024 · Cellular and Molecular Immunology · 被引 40)
• Pyruvate kinase M2 regulates kidney fibrosis through pericyte glycolysis during the progression from acute kidney injury to chronic kidney disease (2023 · Cell Proliferation · 被引 36)
• Care for end-stage kidney disease in China: progress, challenges, and recommendations (2024 · The Lancet Regional Health - Western Pacific · 被引 24)